text:
36th Euro Global Summit and Expo on Vaccines & Vaccination June 03-04, 2019 London, UK
Recommended Global Vaccines Conferences
Vaccines 2020, Canada
Immune Response 2020, UAE
Vaccines R&D 2020, Netherlands
Virologycongress2020, Germany
Euro Vaccines 2020, Germany
Vaccines World 2020, Japan
Day 1: June 3, 2019
Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.
For more Conferences visit www.conferenceseries.com
Abstracts Submission
Theme: Focusing on novel strategies in Vaccines Research and Development
Euro Vaccines 2019
Renowned Speakers
Yanelys Morera Diaz
Center for Genetic Engineering and Biotechnology
J Santiago
Mejia Oxford Immunotec,
Keshan Zhang Lanzhou
Veterinary Research Institute
Geert Vanden Bossche
University Leuven
Chil-Yong Kang
Pramod Jog
Dr. D. Y. Patil Medical College
Periasamy Selvaraj
Emory University School of Medicine
Debaki R Howlader
National Institute of Cholera and Enteric Diseases
Gabriel Kristian Pedersen
Statens Serum Institut
Carmen Alvarez-Dominguez
Instituto de Investigación Marqués de Valdecilla
Frederic J Deschamps
University Hospital of Reims
Randa S Hamadeh
Catherine Heffernan
Pragya Sharma
Maulana Azad Medical College
Helen Bright
Medimmune
Chit Laa Poh
Sunway University
Godwin W Nchinda
CIRCB
Xiao-Song He
VA Palo Alto Health Care System
Mark Fife
The Pirbright Institute
Alan D T Barrett
Jagat R Kanwar
Yoshinori HAYAKAWA
Toin University of Yokohama
Veysel Kayser
Germain J. P. Fernando
Mark Reid
Clinical Network Services (CNS) Pty Ltd
Katie Flanagan
MRC Laboratories
Julie E. Bines
Neena Mitter
Simon John Potter
Spruson & Ferguson
Gilberto Filaci
Peter Timms
Rodolfo M. Alarcón
Istvan Toth
Pharmaceuticals TetraQ
Liliya Pekova
Trakia University
Bita Sedaghat
Mala D. Menon
Bombay College of Pharmacy
Sharareh Eskandari
Bernd Rehm
Institute of Fundamental Sciences
Roy Hall
Kartika Senjarini
University of Jember
Poupak Fallahi
Alexander Khromykh
NHMRC
QIMR Berghofer
Medical Research Institute
Kenneth W Beagley
Pierre A MORGON
MRGN Advisors
Zakaria Hmama
Yuzhang Wu
Institute of Immunology
Helle Bielefeldt-Ohmann
Australian Infectious Diseases Research Centre
Timothy J Mahony
Filip Dubovsky
MedImmune/AstraZeneca
Denise L Doolan
QIMR Berghofer Medial Research Institute
Allan Cripps
Aycan Gundogdu
Erciyes University School of Medicine
Remya Mohanraj
Dan Bustillos
University of Washington Bothell
Alexander Bukreyev
Charles E McKenna
Jay Tischendorf
Qizhi Cathy Yao
Brandon DeKosky
Robert L Hunter
University of Texas Health Sciences Center
Stephanie Planque
University of Texas - Houston Medical Schoo
Pei-Yong Shi
Applied Biotechnology Institute
Giulio Tarro
Foundation T. & L. de Beaumont Bonelli for cancer research
Sudhir Paul
University of Texas - Houston Medical School
James D Cherry
Ana Gervassi
Center for Infectious Disease Research
Chih-Hsiang Lengt
National Health Research Institutes
Genevieve Inchauspe
Transgene SA
Hsin-Wei Chen
Mohammad Hossein Yazdi
Karola Rittner
Fonteneau University of Nantes
Ger T Rijkers
University College Roosevelt
Touraj Aligholipour
Farzani Ankara University
Pascal Breton
VitamFero
Zrinka Oreskovic
Cyrielle Fougeroux
Copenhagen University
Klaus Schwamborn
Valneva SE
Peter Johannes Holst
Brian Abel
A*STAR
Magdalena Tary-Lehmann
Cellular Technology Limited
Kei Amemiya
US Army Medical Research Institute of Infectious Disease
Igor S Lukashevich
Shan Lu
Shreemanta K Parida
Justus-Liebig University
Susanne Rauch
CureVac
Mark Lawrence Johnson
MJ Lawrence Consulting
Leondios G Kostrikis
Lallan Giri
Biologic Resources LLC
Erwann Loret
Aix-Marseille University
Talin Barissani-Asenbauer
Imran Saleem
Gustavo Cabral de Miranda
Morehouse School of Medicine
Yusuf Omosun
Francis Eko
Guanggang Qu
Shandong Binzhou Animal Science and Veterinary Medicine Academy
Massimo Amicosante
University of Rome
Sessions/Tracks
Vaccines Conferences committee look forward to welcoming participants to 36th Euro Global Summit and Expo on Vaccines & Vaccination (Euro Vaccines 2019) during June 03-04, 2019 in London, UK which will bring together world leaders in their respective fields in the fascinating environment of London, UK.
Euro Vaccines 2019 conference features highly enlightening and interactive sessions to encourage the exchange of ideas across a wide range of disciplines in the field of vaccines and therapeutics. The conference includes explicit keynote talks from distinguished scientists, plenary sessions, Poster competition, Young Researcher sessions, Symposiums, Workshop and Exhibitions. There will be opportunities for those chosen to present at the meeting to publish a manuscript based on their presentation in the Journal of Vaccines & Vaccination or its sister publication, Journal of Clinical & Cellular Immunology and Immunome Research. Conference Series llc LTD organizes 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
Vaccines Conference brings together researchers, public health professionals and other key stakeholders to discuss progress and challenges in Vaccines research and development and implementation as identified in the universal Vaccines accomplishment. This event gives a chance for academic and health professionals to gain and share information on Vaccines research and development. We do expect this conference will be an opportunity to meet and gather with colleagues from different countries and other parts of London.
The aim of the conference is to provide an international platform for discussion and debate among Vaccines research and development providers, policy makers, academics and researchers on strategies and initiatives to achieve transformational and sustainable development in Vaccines research and development in local and global contexts.
On behalf of Euro Vaccines 2019, we invite you to take this opportunity to join us for academic exchange and visit the city of London, UK.
Euro Vaccines Conference is aimed to give an opportunity that with scholars from around the world focused on learning about Vaccines & Immunology and its advances; this is the best opportunity to reach the largest assemblage of participants from the Vaccines & Immunology community. It provide an explicit platform for presentations, distribute information, meet with current and potential scientists, make a splash with new vaccines developments, and receive name recognition at this event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Vaccines & Immunology are hallmarks of this conference.
Researchers & Scientists related to Vaccines R&D
Associations and Societies related to Vaccines R&D
Vaccine Manufacturing Companies
Vaccine Developers and Investigators
Deans and Professors
Directors, CEOs, Presidents and Vice Presidents
University Faculty
Medical Schools/Colleges
Nursing Schools/Colleges
Vaccination Programme Organising Government and Non-government Organisations
Medical Devices Manufacturing Companies
Track 1: Human Vaccines - Infectious & Non Infectious Diseases
A vaccine is an inactivated form of bacteria or virus that is injected into the body to simulate an actual infection. Because the injected microorganisms are 'dead,' they don't cause a person to become sick. Instead, vaccines stimulate an immune response by the body that will fight off that type of illness. It covers infectious disease targets and non-infectious disease targets. To generate vaccine-mediated protection is a complex challenge. Currently available vaccines have largely been developed empirically, with little or no understanding on how they activate the immune system. Their early protective efficacy is primarily conferred by the induction of antigen-specific antibodies. However, there is more to antibody-mediated protection than the peak of vaccine-induced antibody titers.
Related Vaccines Conferences | Immunology Conferences | World Vaccine Congress
9th International Conferences on Emerging Infectious Diseases August 27-28, 2018 Hilton Zurich Airport, Zurich, Switzerland; 10th Euro-Global Conferences on Infectious Diseases September 27-29, 2018 Rome, Italy; 14th World Congress on Infection Prevention and Control December 6-7, 2018 Valencia, Spain; Nordic Society 0f Clinical Microbiology and Infectious Diseases Conferences 35th Annual Meeting 2018 August 19-11, 2018 Reykjavík, Iceland; International Conferences on Emerging Infectious Diseases (ICEID) August 26-29 2018, Atlanta, USA; 3rd Gulf Congress of Clinical Microbiology and Infectious Diseases Conferences 2018 November 07-10, 2018 Dubai, UAE; Vaccines Conferences USA 2019 ; Australian College for Infection Prevention and Control Annual Conference November 19-21 2018, Brisbane, Australia; World Congress on Infectious Diseases Conferences and Antibiotics Conferences 2018 November 28-29 2018 Bengaluru, India; Mayo Clinic Infectious Diseases Subspecialties Update 2019 February 04-08, 2019 Waimea, USA; Vaccines Conferences Asia 2019; The European Congress of Clinical Microbiology Conferences and Infectious Diseases April 13-16, 2019 Amsterdam, Netherlands
Related Societies:
European Society for Paediatric Infectious Diseases; European Union Geriatric Medicine Society; European Federation of Immunological Societies; European Academy of Allergy and Clinical Immunology; Royal Society of London; Epidemiological Society of London; Edward Jenner Society
The Anti-Vaccination Society of America; Infectious Diseases Society of America; Association of Immunization Managers; Clinical Immunology Society
Asia and Middle-East:
Japanese Society for Immunology; Singaporean Society for Immunology; Australasian Society of Clinical Immunology and Allergy
Track 2: Vaccine Research & Development
Vaccine Development is an activity that focuses on a variety of technological initiatives and applied research, which enhance and promote improved systems and practices for vaccine safety. In the past year, the unprecedented Ebola disease outbreak galvanized research and industry response and as we continue to search for solutions, we must review the lessons learned in order to overcome the current challenges. Vaccines development is a long, complex process, often lasting 10-15 years and involving a combination of public and private involvement. The current system for developing, testing, and regulating vaccines developed during the 20th century as the groups involved standardized their procedures and regulations.
10th International Conferences on Clinical and Cellular Immunology August 6-7, 2018 Madrid, Spain; 11th Annual Congress on Immunology & Immunotechnology September 13-14, 2018 Zurich, Switzerland; 10th Molecular Immunology & Immunogenetics Congress March 04-05, 2019 Barcelona, Spain; 10th European Immunology Conferences June 13-14, 2019 Berlin, Germany; Vaccines Conferences Australia 2019; 19th Annual Colorado Immunology Conferences August 29-31, 2018 Colorado, USA; 5th European Congress of Immunology September 02-05, 2018 Amsterdam, The Netherlands; Frontiers of Immunology in Health & Disease September 10-14, 2018 Suzhou, China; 17th International Congress of Immunology October 18-23, 2018 Beijing, China; Vaccines Conferences USA 2019; Tumor Immunology and Immunotherapy Conferences November 27-30, 2018 Florida, USA; Innate Immune Receptors: Roles in Immunology and Beyond March 10-14, 2019 Taipei, Taiwan
European Academy of Paediatrics; European Malaria Foundation (e-malaria Foundation); European Malaria Vaccine Development (EUROMALVAC); European malaria Vaccine Initiative (EMVI)
Autism Science Foundation (ASF); Childhood Influenza Immunization Coalition (CIIC); Edward Jenner Vaccine Society; Global Polio Eradication Initiative
Lebanese Society of Allergy and Immunology; Moldavian Society of Allergology & Immunology; Moroccan Society of Allergology and Clinical Immunology
Track 3: Next-Generation Vaccine Delivery Technologies
Drug delivery systems are engineered technologies for the targeted delivery and/or controlled release of therapeutic agents. Drugs have long been used to improve health and extend lives. The practice of drug delivery has changed dramatically in the last few decades and even greater changes are anticipated in the near future. Biomedical engineers have not only contributed substantially to our understanding of the physiological barriers to efficient drug delivery—such as transport in the circulatory system and drug movement through cells and tissues—they have contributed to the development of a number of new modes of drug delivery that have entered clinical practice. Role of vaccine delivery technologies includes rational development of vaccines, achieving immunization goals, supporting best clinical practice.
Vaccines continue to revolutionize our ability to prevent disease and improve health. With every technological advance, we are able to extend the benefits of vaccines to more people and provide better protection from life-threatening infectious diseases.
32nd International Conferences on Vaccines and Immunization March 21-22, 2019 Rome, Italy; Vaccines ConferencesJune 03-04, 2019 London, UK; ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance September 4-7 2018, Lisbon, Portugal; 12th Vaccine Congress September 16-19, 2018 Budapest, Hungary; International Conferences on Immunology & Vaccination September 17-19, 2018 Paris, France; Vaccines Conferences Middle east 2019; 2018 International Society for Vaccines (ISV) Annual Congress October 28-30 2018 Georgia, USA; World Congress on Vaccines October 29-31, 2018, Washington DC, USA; 4th International Conference on Vaccines Research & Development November 13-15, 2018 in Baltimore, USA; Canadian Immunization Conferences 2018 December 04–06, 2018 Ontario, Canada; Molecular Approaches to Vaccines and Immune Monitoring February 10-14, 2019 Colorado, USA; Vaccines Conferences Canada 2019; 9th Annual Vaccines World Summit 2019 February 12-13, 2019 Hyderabad, India; 3rd Global Vaccines Research & Development Conferences March 25-26, 2019 Milan, Italy; World Vaccine Congress Washington 2019 April 14-17, 2019 Washington DC, USA
European Society for Immunodeficiency; French Society of Immunology; Immunology of Diabetes Society; Deutsche Gesellschaft für Immunologie
American Academy of Paediatrics (AAP); American College Health Association (ACHA); Association of Immunization Managers (AIM); Association for Professionals in Infection Control and Epidemiology (APIC)
Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAPARI); Asia Pacific Association of Pediatric Allergy, Respirology and Immunology (APAPARI); Commonwealth of Independent States Society of Allergology and Immunology (CIS Society)
Track 4: Vaccines safety & Efficacy
Vaccines are the best defense we have against serious, preventable, and sometimes deadly contagious diseases. Vaccines are some of the safest medical products available, but like any other medical product, there may be health risk. Accurate information about the value of vaccines as well as their possible side-effects helps people to make informed decisions about vaccination. The safety of vaccines is carefully monitored, starting early in the product development and continuing for as long as the vaccine is being used. Find out about what is done before and after vaccines are approved for use and what is known about the benefits and safety of specific vaccines. There is a lot of false information about vaccines safety on the Internet. This can be confusing. Discover the answers to common questions and concerns about vaccines.
32nd International Conferences on Vaccines and Immunization March 21-22, 2019 Rome, Italy; Vaccines ConferencesJune 03-04, 2019 London, UK; ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance September 4-7 2018, Lisbon, Portugal; Vaccines Conferences Asia 2019; 12th Vaccine Congress September 16-19, 2018 Budapest, Hungary; International Conferences on Immunology & Vaccination September 17-19, 2018 Paris, France; 2018 International Society for Vaccines (ISV) Annual Congress October 28-30 2018 Georgia, USA; World Congress on Vaccines October 29-31, 2018, Washington DC, USA; 4th International Conference on Vaccines Research & Development November 13-15, 2018 in Baltimore, USA; Canadian Immunization Conferences 2018 December 04–06, 2018 Ontario, Canada; Molecular Approaches to Vaccines and Immune Monitoring February 10-14, 2019 Colorado, USA; Vaccines Conferences Australia 2019; 9th Annual Vaccines World Summit 2019 February 12-13, 2019 Hyderabad, India; 3rd Global Vaccines Research & Development Conferences March 25-26, 2019 Milan, Italy; World Vaccine Congress Washington 2019 April 14-17, 2019 Washington DC, USA
Croatian Society of Allergology and Clinical Immunology; Czech Society of Allergology and Clinical Immunology; Finnish Society of Allergology and Clinical Immunology; French Society of Allergology and Clinical Immunology
Panamanian Association of Allergology and Clinical Immunology; Paraguayan Society of Allergy, Asthma, and Immunology; Peruvian Society of Allergy and Immunology; Venezuelan Society of Allergy, Asthma and Immunology
Philippine Society of Allergy, Asthma and Immunology; Taiwan Academy of Pediatric Allergy Asthma Immunology; Vietnam Association of Allergy, Asthma and Clinical Immunology
Track 5: Vaccines Business Development
Collaboration plays a major part in the success of Vaccines Business. This is exemplified in the relationships built, products launched and lives improved.
Vaccines Business development: comprise a number of tasks and processes generally aiming at developing and implementing growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory. Vaccine development programs face several challenges that set them apart from other types of healthcare product development programs.
9th International Conferences on Emerging Infectious Diseases August 27-28, 2018 Hilton Zurich Airport, Zurich, Switzerland; 10th Euro-Global Conferences on Infectious Diseases September 27-29, 2018 Rome, Italy; 14th World Congress on Infection Prevention and Control December 6-7, 2018 Valencia, Spain; Nordic Society 0f Clinical Microbiology and Infectious Diseases Conferences 35th Annual Meeting 2018 August 19-11, 2018 Reykjavík, Iceland; International Conferences on Emerging Infectious Diseases (ICEID) August 26-29 2018, Atlanta, USA; Vaccines Conferences Asia 2019; 3rd Gulf Congress of Clinical Microbiology and Infectious Diseases Conferences 2018 November 07-10, 2018 Dubai, UAE; Vaccines Conferences USA 2019 ; Australian College for Infection Prevention and Control Annual Conference November 19-21 2018, Brisbane, Australia; World Congress on Infectious Diseases Conferences and Antibiotics Conferences 2018 November 28-29 2018 Bengaluru, India; Mayo Clinic Infectious Diseases Subspecialties Update 2019 February 04-08, 2019 Waimea, USA; Vaccines Conferences Asia 2019; Vaccines Conferences USA 2019; The European Congress of Clinical Microbiology Conferences and Infectious Diseases April 13-16, 2019 Amsterdam, Netherlands
Track 6: Vaccine Adjuvants
Vaccine adjuvants – is an ingredient of a vaccine that helps create a stronger immune response in the patient's body. In other words, adjuvants help vaccines work better. Some vaccines made from weakened or dead germs contain naturally occurring adjuvants and help the body produce a strong protective immune response. However, most vaccines developed today include just small components of germs, such as their proteins, rather than the entire virus or bacteria. These vaccines often must be made with adjuvants to ensure the body produces an immune response strong enough to protect the patient from the germ he or she is being vaccinated against. Aluminum gels or aluminum salts are vaccines ingredients that have been used in vaccines since the 1930s. Small amounts of aluminum are added to help the body build stronger immunity against the germ in the vaccine. Aluminum is one of the most common metals found in nature and is present in air, food, and water. The amount of aluminum present in vaccines is low and is regulated by the U.S. Food and Drug Administration (FDA).
10th International Conferences on Clinical and Cellular Immunology August 6-7, 2018 Madrid, Spain; 11th Annual Congress on Immunology & Immunotechnology September 13-14, 2018 Zurich, Switzerland; 10th Molecular Immunology & Immunogenetics Congress March 04-05, 2019 Barcelona, Spain; Vaccines Conferences Middle east 2019; 10th European Immunology Conferences June 13-14, 2019 Berlin, Germany; 19th Annual Colorado Immunology Conferences August 29-31, 2018 Colorado, USA; 5th European Congress of Immunology September 02-05, 2018 Amsterdam, The Netherlands; Frontiers of Immunology in Health & Disease September 10-14, 2018 Suzhou, China; 17th International Congress of Immunology October 18-23, 2018 Beijing, China; Tumor Immunology and Immunotherapy Conferences November 27-30, 2018 Florida, USA; Vaccines Conferences Australia 2019; Innate Immune Receptors: Roles in Immunology and Beyond March 10-14, 2019 Taipei, Taiwan
European Society for Immunodeficiency; French Society of Immunology; Immunology of Diabetes Society;Deutsche Gesellschaft für Immunologie; Royal Society of London; Epidemiological Society of London;Edward Jenner Society
Track 7: HIV/AIDS Vaccines
An AIDS vaccine does not yet exist, but efforts to develop a vaccine against HIV, the virus that causes AIDS, have been underway for many years. An HIV vaccine could be effective in either of two ways. A "preventive" vaccine would stop HIV infection occurring altogether, whereas a "therapeutic" vaccine would not stop infection, but would prevent or delay illness in people who do become infected, and might also reduce the risk of them transmitting the virus to other people. Although a preventive vaccine would be ideal, therapeutic vaccines would also be highly beneficial. The basic idea behind all HIV vaccines is to encourage the human immune system to fight HIV.
32nd International Conferences on Vaccines and Immunization March 21-22, 2019 Rome, Italy; Vaccines ConferencesJune 03-04, 2019 London, UK; ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance September 4-7 2018, Lisbon, Portugal; Vaccines Conferences Canada 2019; 12th Vaccine Congress September 16-19, 2018 Budapest, Hungary; International Conferences on Immunology & Vaccination September 17-19, 2018 Paris, France; 2018 International Society for Vaccines (ISV) Annual Congress October 28-30 2018 Georgia, USA; World Congress on Vaccines October 29-31, 2018, Washington DC, USA; 6th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs August 27-28, 2018 Hilton Zurich Airport, Zurich, Switzerland; Vaccines Conferences Asia 2019; 9th International Workshop on HIV & Aging 2018 September 13-14, 2018, New York, USA; Australasian HIV & AIDS Conferences 2018 September 24-26, 2018 Sydney, Australia; British HIV Association Autumn Conference 2018 October 04-05, 2018, London, UK; HIV Research Conferences (HIVR4P 2018) October 21-25, 2018 Madrid, Spain; HIV Drug Therapy Glasgow 2018 October 28- 31, 2018 Glasgow, UK; HIV Vaccines ConferencesMarch 24 - 28, 2019 | British Columbia, Canada
Track 8: Immunology/Animal Models
Observations in animal models have substantially advanced our knowledge of immune system adaptation, changes during the aging process, and age-associated degenerative diseases with autoimmune characteristics.
Animal models provided early proof that discrimination of self (that which the immune system identifies as belonging to the body) and non-self (that which the immune system identifies as foreign to the body) is determined not entirely at conception, but, to a large extent, during early fetal development by a process called immune adaptation. The animal experiments confirmed the premise that immune adaptation is determined by the fetal or neonatal environment, rather than inherited. Animal models have substantially enhanced our understanding of the role of the immune system in tissue physiology and pathology. The knowledge gained from animal models offers hope for future modification of the human immune system to combat a number of disease processes.
10th International Conferences on Clinical and Cellular Immunology August 6-7, 2018 Madrid, Spain; 11th Annual Congress on Immunology & Immunotechnology September 13-14, 2018 Zurich, Switzerland; 10th Molecular Immunology & Immunogenetics Congress March 04-05, 2019 Barcelona, Spain; 10th European Immunology Conferences June 13-14, 2019 Berlin, Germany; Vaccines Conferences Asia 2019; 19th Annual Colorado Immunology Conferences August 29-31, 2018 Colorado, USA; 5th European Congress of Immunology September 02-05, 2018 Amsterdam, The Netherlands; Frontiers of Immunology in Health & Disease September 10-14, 2018 Suzhou, China; Vaccines Conferences Canada 2019; 17th International Congress of Immunology October 18-23, 2018 Beijing, China; Tumor Immunology and Immunotherapy Conferences November 27-30, 2018 Florida, USA; Innate Immune Receptors: Roles in Immunology and Beyond March 10-14, 2019 Taipei, Taiwan
British Society for Immunology; Microbiology Society, London; Royal Society of London; Epidemiological Society of London; Edward Jenner Society; Society for Applied Microbiology; European Society of Clinical Microbiology and Infectious Diseases
The Federation of Clinical Immunology Societies; The American Association of Immunologists; American Society for Microbiology; Colombian Allergy, Asthma and Immunology Association; Canadian Society for Immunology
Indian society of Allergy, Asthma and Clinical Immunology; Australasian Society of Clinical Immunology and Allergy; Bangladesh Society of Allergy and Immunology
Track 9: Childhood Vaccines and Maternal Vaccines
Vaccination given to children is called children Immunization. It is currently recommended that all children receive vaccination against the infectious diseases unless the child has special circumstances, such as a compromised immune system or neurological disorders. In our mobile society, over a million people each day people travel to and from other countries, where many vaccine-preventable diseases remain relatively common. Without vaccines, epidemics of many preventable diseases could return, resulting in increased - and unnecessary - illness, disability, and death among children.
We have record or near record low levels of vaccine-preventable childhood diseases in the United States, but that does not mean these have disappeared. Many of the viruses and bacteria are still circulating in this country or are only a plane ride away. That's why it's important that children, especially infants and young children receive recommended immunizations on time.
Vaccines can help keep you and your growing family healthy. If you are pregnant or planning a pregnancy, the specific vaccinations you need are determined by factors such as your age, lifestyle, medical conditions you may have, such as asthma or diabetes, type and locations of travel, and previous vaccinations. Benefits of vaccinating pregnant women usually outweigh potential risks when the likelihood of disease exposure is high, when infection would pose a risk to the mother or fetus, and when the vaccine is unlikely to cause harm. All women who will be pregnant (any trimester) during the flu season should be offered this vaccine. Talk to your doctor to see if this applies to you. Tetanus/Diphtheria/Pertussis (Tdap): Tdap is recommended during pregnancy, preferably between 27 and 36 weeks' gestation, to protect baby from whooping cough.
20th International Conferences on Pediatrics & Primary Care September 03-04, 2018 Zurich, Switzerland; 24thEuropean Pediatrics Conferences September 10-11, 2018 Copenhagen, Denmark; 26th International Conferences on Neonatology and perinatology November 15-17, 2018 Edinburgh, Scotland; 4th International Conferences on Pediatrics and Pediatric Surgery April 22-23, 2019 London, UK; Vaccines Conferences USA 2019; 27th International Conferences on Clinical Pediatrics 10-June-2019 Berlin, Germany; 7th International Chronic Obstructive Pulmonary Disease Conferences October 22-23, 2018 Rome, Italy; 15th Asian Society of Paediatric Anaesthesiologists Conferences August17-19 2018 Bangkok, Thailand; 10th Asia Pacific Paediatric Endocrine Society Scientific Meeting 2018 November 07-10 2018 Chiang Mai, Thailand; 9th Asian Congress of Paediatric Infectious Diseases Conferences2018 November 10-12, 2018 Fukuoka, Japan; 50th Congress of the International Society of Paediatric Oncology Conferences 2018 November 16-19 2018 Kyoto, Japan; Vaccines Conferences Asia 2019; 10th Annual Conference on Emergencies & Challenges in Pediatrics December 14-15, 2018 New York City, New York; 23rd Annual Spring Conference on Pediatric Emergencies April 3-6, 2019 Kauai, Hawaii
Track 10: Human Preventive & Therapeutic Vaccines
A preventative vaccine is administered to a person who is free of the targeted infection. By introducing a part of the virus or an inactive virus (which acts like a decoy) into the body, the immune system reacts by producing antibodies. Preventive vaccines are widely used to prevent diseases like polio, chicken pox, measles, mumps, rubella, influenza (flu), and hepatitis A and B.
In addition to preventive vaccines, there are also "therapeutic vaccines". These are vaccines that are designed to treat people who already have a disease. Some scientists prefer to refer to therapeutic vaccines as "therapeutic immunogens.
9th International Conferences on Emerging Infectious Diseases August 27-28, 2018 Hilton Zurich Airport, Zurich, Switzerland; 10th Euro-Global Conferences on Infectious Diseases September 27-29, 2018 Rome, Italy; 14th World Congress on Infection Prevention and Control December 6-7, 2018 Valencia, Spain; Vaccines Conferences Australia 2019; Nordic Society 0f Clinical Microbiology and Infectious Diseases Conferences 35th Annual Meeting 2018 August 19-11, 2018 Reykjavík, Iceland; International Conferences on Emerging Infectious Diseases (ICEID) August 26-29 2018, Atlanta, USA; 3rd Gulf Congress of Clinical Microbiology and Infectious Diseases Conferences 2018 November 07-10, 2018 Dubai, UAE; Vaccines Conferences USA 2019 ; Australian College for Infection Prevention and Control Annual Conference November 19-21 2018, Brisbane, Australia; Vaccines Conferences Middle east 2019; World Congress on Infectious Diseases Conferences and Antibiotics Conferences 2018 November 28-29 2018 Bengaluru, India; Mayo Clinic Infectious Diseases Subspecialties Update 2019 February 04-08, 2019 Waimea, USA; Vaccines Conferences Asia 2019; The European Congress of Clinical Microbiology Conferences and Infectious Diseases April 13-16, 2019 Amsterdam, Netherlands
Swiss Society for Microbiology; Federation of European Microbiological Societies; International Society of Vaccines; International Union of Immunological Society; Royal Society of London; Epidemiological Society of London; Edward Jenner Society
Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy, Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clincial Immunology
Indonesian Society of Allergy and Immunology; Korean Academy of Asthma, Allergy and Clinical Immunology; Malaysian Society of Allergy and Immunology
Track 11: Cancer Vaccines and Immunotherapy
Immunotherapeutics is treatment that uses your body's own immune system to help fight cancer. Get information about the different types of immunotherapy and the types of cancer they are used to treat. The main types of immunotherapy now being used to treat cancer include:
Other, non-specific immunotherapies
Some types of immunotherapy are also sometimes called biologic therapy or biotherapy.
In the last few decades immunotherapy has become an important part of treating some types of cancer. Newer types of immune treatments are now being studied, and they'll impact how we treat cancer in the future.
Immunotherapy includes treatments that work in different ways. Some boost the body's immune system in a very general way. Others help train the immune system to attack cancer cells specifically. Immunotherapy works better for some types of cancer than for others. It's used by itself for some of these cancers, but for others it seems to work better when used with other types of treatment.
36th World Cancer Conferences October 11-13, 2018 Zurich, Switzerland; 13th World Biomarkers Congress November 29-30, 2018 Dublin, Ireland; 4th International Congress on Epigenetics & Chromatin September 03-05, 2018 London, UK; 28th Euro Congress on Cancer Science & Therapy March 07-08, 2019 Barcelona, Spain; Vaccines Conferences Canada 2019; Global Conference on Cancer Research & Therapy (GCCRT- 2018) September 06-07, 2018 Venice, Italy; ECCO2018 (European Cancer Summit) September 7-9, 2018 Vienna, Austria; 2018 World Cancer Congress October 01-04, 2018 Kuala Lumpur, Malaysia; Early Detection of Cancer Conference October 02–04, 2018 Portland, USA; NCRI Cancer Conferences November 04-06 2018 Glasgow, UK; Cancer Vaccines Conferences January 20-24, 2019 Vancouver, Canada; Vaccines Conferences USA 2019; Uncovering Mechanisms from Immune-Based Therapy in Cancer and Autoimmunity February 18-22, 2019 Colorado, USA; 2019 ASCO-SITC Clinical Immuno-Oncology Symposium February 28-March 02, 2019 California, USA; Cancer Immunotherapy Conferences: Mechanistic Insights to Improve Clinical Benefit March 10-14, 2019 British Columbia, Canada
Track 12: Vaccines for Vector-borne Diseases
Vaccines that target blood-feeding disease vectors, such as mosquitoes and ticks, have the potential to protect against the many diseases caused by vector-borne pathogens. Vector-borne diseases are among the most complex of all infectious diseases to prevent and control. Vector- borne diseases, most of which are transmitted in and around the home, are best controlled by a combination of vector control (use of public health insecticides on bednets, or by spraying), medicines and vaccines.
Historically, successful vector-borne disease prevention resulted from management or elimination of vector populations. Malaria was driven out of the USA and most of Europe in this way. Where vector control has been consistently applied in the past, the results have been dramatic, especially with early efforts to control malaria by spraying the inside surfaces of houses with insecticides. Indoor Residual Spraying (IRS) and long-lasting insecticide treated bednets have been very effective over the last 10 years and are widely regarded as one of the main contributors to the more than 1 million lives saved.
In contrast to expenditure and effort on medicine, diagnostic and vaccine development, relatively little attention was given to vector control in the past. The foresighted establishment of IVCC in 2005, with a grant from the Bill and Melinda Gates Foundation began the process of bringing Vector Control into the mainstream strategy for future eradication of malaria and other vector-borne diseases.
32nd International Conferences on Vaccines and Immunization March 21-22, 2019 Rome, Italy; Vaccines ConferencesJune 03-04, 2019 London, UK; ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance September 4-7 2018, Lisbon, Portugal; Vaccines Conferences Asia 2019; 12th Vaccine Congress September 16-19, 2018 Budapest, Hungary; International Conferences on Immunology & Vaccination September 17-19, 2018 Paris, France; 2018 International Society for Vaccines (ISV) Annual Congress October 28-30 2018 Georgia, USA; World Congress on Vaccines October 29-31, 2018, Washington DC, USA; 4th International Conference on Vaccines Research & Development November 13-15, 2018 in Baltimore, USA; Vaccines Conferences Middle east 2019; Canadian Immunization Conferences 2018 December 04–06, 2018 Ontario, Canada; Molecular Approaches to Vaccines and Immune Monitoring February 10-14, 2019 Colorado, USA; 9th Annual Vaccines World Summit 2019 February 12-13, 2019 Hyderabad, India; Vaccines Conferences Australia 2019; 3rd Global Vaccines Research & Development Conferences March 25-26, 2019 Milan, Italy; World Vaccine Congress Washington 2019 April 14-17, 2019 Washington DC, USA
European Academy of Allergy and Clinical Immunology (EAACI); European Molecular Biology Laboratory (EMBL); Medical Research Council (MRC); Royal Society of London; Epidemiological Society of London; Edward Jenner Society
Hepatitis B Foundation (HBF); Infectious Diseases Society of America (IDSA); National Adult and Influenza Immunization Summit (NAIIS); National Foundation for Infectious Diseases (NFID); Paediatrics Infectious Diseases Society (PIDS)
Russian Association of Allergology and Clinical Immunology; Turkish National Society of Allergy and Clinical Immunology; Ukrainian Association of Allergologists and Clinical Immunologists
Track 13: Vaccines for Older Adults
Vaccines are an important part of routine preventive care for older adults, but most adults don't get their vaccines as recommended. Omitting vaccination leaves adults needlessly vulnerable to severe illnesses, long-term suffering and death from preventable infections. Vaccines are recommended for adults of all ages, they are particularly important for older persons who are at great risk of serious debilitating consequences and death from infectious diseases. Vaccination is particularly important for individuals living in nursing homes or assisted living facilities, as disease can spread easily among people in close proximity.
10th International Conferences on Clinical and Cellular Immunology August 6-7, 2018 Madrid, Spain; 11th Annual Congress on Immunology & Immunotechnology September 13-14, 2018 Zurich, Switzerland; 10th Molecular Immunology & Immunogenetics Congress March 04-05, 2019 Barcelona, Spain; 10th European Immunology Conferences June 13-14, 2019 Berlin, Germany; 19th Annual Colorado Immunology Conferences August 29-31, 2018 Colorado, USA; Vaccines Conferences Canada 2019; 5th European Congress of Immunology September 02-05, 2018 Amsterdam, The Netherlands; Vaccines Conferences USA 2019; Frontiers of Immunology in Health & Disease September 10-14, 2018 Suzhou, China; 17th International Congress of Immunology October 18-23, 2018 Beijing, China; Tumor Immunology and Immunotherapy Conferences November 27-30, 2018 Florida, USA; Innate Immune Receptors: Roles in Immunology and Beyond March 10-14, 2019 Taipei, Taiwan
British Society for Allergy and Clinical Immunology; British Society for Histocompatibility and Immunogenetics; European Federation of Immunological Societies; European Academy of Allergology and Clinical Immunology
Voices for Vaccines (VFV); National Institute of Allergy and Infectious Disease (NIAID); American Public Health Association (APHA); American Association for the Advancement of Science (AAAS); American Society for Microbiology (ASM)
Australasian Society for Immunology; Australasian Society of Clinical Immunology and Allergy; Israel Association of Allergy and Clinical Immunology; Jordanian Society for Allergy and Clinical Immunology; Japanese Society for Immunology
Track 14: Veterinary vaccines
Veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. Several vaccine types can de distinguished among the second-generation veterinary vaccines, depending whether they are live or inactivated, according to the strain of rabies virus used and the characteristics of the cell substrate chosen for viral replication. More recently a third generation of live veterinary rabies vaccine has been developed using recombinant technology. Depending upon the expression system these vaccines are used either parenterally or orally. Oral rabies vaccines are widely used in foxes in Europe and in racoons in the USA.
9th International Conferences on Emerging Infectious Diseases August 27-28, 2018 Hilton Zurich Airport, Zurich, Switzerland; 10th Euro-Global Conferences on Infectious Diseases September 27-29, 2018 Rome, Italy; Vaccines Conferences Asia 2019; 14th World Congress on Infection Prevention and Control December 6-7, 2018 Valencia, Spain; Nordic Society 0f Clinical Microbiology and Infectious Diseases Conferences 35th Annual Meeting 2018 August 19-11, 2018 Reykjavík, Iceland; International Conferences on Emerging Infectious Diseases (ICEID) August 26-29 2018, Atlanta, USA; 3rd Gulf Congress of Clinical Microbiology and Infectious Diseases Conferences 2018 November 07-10, 2018 Dubai, UAE; Vaccines Conferences USA 2019 ; Australian College for Infection Prevention and Control Annual Conference November 19-21 2018, Brisbane, Australia; World Congress on Infectious Diseases Conferences and Antibiotics Conferences 2018 November 28-29 2018 Bengaluru, India; Vaccines Conferences Middle east 2019; Mayo Clinic Infectious Diseases Subspecialties Update 2019 February 04-08, 2019 Waimea, USA; Vaccines Conferences Asia 2019; The European Congress of Clinical Microbiology Conferences and Infectious Diseases April 13-16, 2019 Amsterdam, Netherlands
European Academy of Allergy and Clinical Immunology (EAACI); European Molecular Biology Laboratory (EMBL); Medical Research Council (MRC)
Track 15: Vaccines against Viral and Bacterial Diseases
Most vaccines against viral infection are effective at preventing disease. However, they are not 100% effective for a number of reasons, reactions can occur after vaccinations.
It is difficult for many of us today to appreciate the dangers of childhood viral infections.
Most of the vaccines in use against viruses are very effective at preventing disease. However, for a variety of reasons, they can fail:
The vaccine becomes inactive due to incorrect storage, if used past its expiry date, or if incorrectly administered.
Individuals unpredictably fail to produce an adequate immune response to the vaccine.
Vaccine immunity "fades" over time.
The different vaccine combinations at each time point do not interfere with one another and there is no increased risk of serious side-effects when they are given at the same time.
Bacterial vaccines contain killed or attenuated bacteria that activate the immune system. Antibodies are built against that particular bacteria, and prevents bacterial infection later.
Most vaccines against bacterial infections are effective at preventing disease, reactions can occur after vaccinations. Vaccines are available against tuberculosis, diphtheria, tetanus, pertussis, Haemophilus influenzae type B, cholera, typhoid, and Streptococcus pneumoniae.
32nd International Conferences on Vaccines and Immunization March 21-22, 2019 Rome, Italy; Vaccines ConferencesJune 03-04, 2019 London, UK; ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance September 4-7 2018, Lisbon, Portugal; 12th Vaccine Congress September 16-19, 2018 Budapest, Hungary; Vaccines Conferences Australia 2019; International Conferences on Immunology & Vaccination September 17-19, 2018 Paris, France; 2018 International Society for Vaccines (ISV) Annual Congress October 28-30 2018 Georgia, USA; World Congress on Vaccines October 29-31, 2018, Washington DC, USA; 4th International Conference on Vaccines Research & Development November 13-15, 2018 in Baltimore, USA; Canadian Immunization Conferences 2018 December 04–06, 2018 Ontario, Canada; Vaccines Conferences Canada 2019; Molecular Approaches to Vaccines and Immune Monitoring February 10-14, 2019 Colorado, USA; 9th Annual Vaccines World Summit 2019 February 12-13, 2019 Hyderabad, India; 3rd Global Vaccines Research & Development Conferences March 25-26, 2019 Milan, Italy; World Vaccine Congress Washington 2019 April 14-17, 2019 Washington DC, USA
European Society for Paediatric Infectious Diseases; European Union Geriatric Medicine Society; European Federation of Immunological Societies; European Academy of Allergy and Clinical Immunology
The Anti-Vaccination Society of America; Royal Society of London; Epidemiological Society of London; Edward Jenner Society; Infectious Diseases Society of America; Association of Immunization Managers; Clinical Immunology Society
Track 16: Vaccines for Respiratory Diseases
Population protection by vaccination against infections has been one of the major achievements of public health and is of considerable importance in controlling respiratory diseases.
9th International Conferences on Emerging Infectious Diseases August 27-28, 2018 Hilton Zurich Airport, Zurich, Switzerland; 10th Euro-Global Conferences on Infectious Diseases September 27-29, 2018 Rome, Italy; 14th World Congress on Infection Prevention and Control December 6-7, 2018 Valencia, Spain; World Congress on Infectious Diseases Conferences and Antibiotics Conferences 2018 November 28-29 2018 Bengaluru, India; Mayo Clinic Infectious Diseases Subspecialties Update 2019 February 04-08, 2019 Waimea, USA; 11th Australasian Viral Hepatitis Conferences August 13-15 2018, Adelaide, Australia; Vaccines Conferences USA 2019; 7th International Symposium on Hepatitis Care Conferences in Substance Users September 19-21 2018, Cascais, Portugal; Hepatitis C Virus and Related Viruses 25th International Symposium 2018 October 08-11 2018, Dublin, Ireland; Vaccines Conferences Asia 2019; International Hepatitis B Cure Meeting 2018 November 07, 2018 Toronto, Canada; Australasian Tuberculosis Conferences August 30-31 2018, Wellington, New Zealand
Track 17: Plant-based vaccines
Plant-based vaccines are recombinant protein subunit vaccines. Ideally, the choice of plant species used to produce the selected antigen should allow for oral drug delivery in the form of an edible vaccine. To date, the most advanced human vaccine projects have successfully completed phase I clinical trials, and animal vaccine projects have given promising data in early phase trials targeting specific animal species.
The plant-based vaccine production method works by isolating a specific antigen protein, one that triggers a human immune response from the targeted virus. A gene from the protein is transferred to bacteria, which are then used to "infect" plant cells. The plants then start producing the exact protein that will be used for vaccinations. The flexibility of the plant expressed vaccine system, combined with its low cost and ability to massively scale may provide vaccine protection not only to citizens of the United States, but to many parts of the world that cannot currently afford vaccines. Other uses of plant expressed vaccines including the successful creation of edible bananas that protect against the Norwalk virus.
36th World Cancer Conferences October 11-13, 2018 Zurich, Switzerland; 13th World Biomarkers Congress November 29-30, 2018 Dublin, Ireland; 4th International Congress on Epigenetics & Chromatin September 03-05, 2018 London, UK; 28th Euro Congress on Cancer Science & Therapy March 07-08, 2019 Barcelona, Spain; Global Conference on Cancer Research & Therapy (GCCRT- 2018) September 06-07, 2018 Venice, Italy; ECCO2018 (European Cancer Summit) September 7-9, 2018 Vienna, Austria; 2018 World Cancer Congress October 01-04, 2018 Kuala Lumpur, Malaysia; Vaccines Conferences Canada 2019; Early Detection of Cancer Conference October 02–04, 2018 Portland, USA; NCRI Cancer Conferences November 04-06 2018 Glasgow, UK; Cancer Vaccines Conferences January 20-24, 2019 Vancouver, Canada; Uncovering Mechanisms from Immune-Based Therapy in Cancer and Autoimmunity February 18-22, 2019 Colorado, USA; Vaccines Conferences USA 2019; 2019 ASCO-SITC Clinical Immuno-Oncology SymposiumFebruary 28-March 02, 2019 California, USA; Cancer Immunotherapy Conferences: Mechanistic Insights to Improve Clinical Benefit March 10-14, 2019 British Columbia, Canada
Track 18: DNA Vaccines
DNA vaccination is a technique for protecting an animal against disease by injecting it with genetically engineered DNA so cells directly produce an antigen, resulting in a protective immunological response.
Vaccination consists of stimulating the immune system with an infectious agent, or components of an infectious agent, modified in such a manner that no harm or disease is caused, but ensuring that when the host is confronted with that infectious agent, the immune system can adequately neutralize it before it causes any ill effect. For over a hundred years vaccination has been effected by one of two approaches: either introducing specific antigens against which the immune system reacts directly; or introducing live attenuated infectious agents that replicate within the host without causing disease synthesize the antigens that subsequently prime the immune system.
The field of DNA vaccination is developing rapidly. Vaccines currently being developed use not only DNA, but also include adjuncts that assist DNA to enter cells, target it towards specific cells, or that may act as adjuvants in stimulating or directing the immune response. Ultimately, the distinction between a sophisticated DNA vaccine and a simple viral vector may not be clear. Many aspects of the immune response generated by DNA vaccines are not understood. However, this has not impeded significant progress towards the use of this type of vaccine in humans, and clinical trials have begun.
32nd International Conferences on Vaccines and Immunization March 21-22, 2019 Rome, Italy; Vaccines ConferencesJune 03-04, 2019 London, UK; ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance September 4-7 2018, Lisbon, Portugal; Vaccines Conferences Asia 2019; 12th Vaccine Congress September 16-19, 2018 Budapest, Hungary; International Conferences on Immunology & Vaccination September 17-19, 2018 Paris, France; 2018 International Society for Vaccines (ISV) Annual Congress October 28-30 2018 Georgia, USA; World Congress on Vaccines October 29-31, 2018, Washington DC, USA; 4th International Conference on Vaccines Research & Development November 13-15, 2018 in Baltimore, USA; Vaccines Conferences Middle east 2019; Canadian Immunization Conferences 2018 December 04–06, 2018 Ontario, Canada; Molecular Approaches to Vaccines and Immune Monitoring February 10-14, 2019 Colorado, USA; 9th Annual Vaccines World Summit 2019 February 12-13, 2019 Hyderabad, India; 3rd Global Vaccines Research & Development Conferences March 25-26, 2019 Milan, Italy; World Vaccine Congress Washington 2019 April 14-17, 2019 Washington DC, USA
Albanian Society of Allergology and Clinical Immunology; Austrian Society of Allergology and Immunology;Belgian Society of Allergy and Clinical Immunology; British Society of Allergy and Clinical Immunology;Royal Society of London; Epidemiological Society of London; Edward Jenner Society
Argentine Association of Allergy and Immunology; Argentine Society of Allergy and Immunology; Brazilian Society of Allergy and Immunology; Chilean Society of Allergy and Immunology
Allergy & Immunology Society of Sri Lanka; Allergy and Clinical Immunology Society of Singapore; Allergy and Immunology Society of Thailand
Track 19: Hepatitis Vaccines
Hepatitis is an inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer. Hepatitis viruses are the most common cause of hepatitis in the world but other infections, toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases can also cause hepatitis.
There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.
Hepatitis A and E are typically caused by ingestion of contaminated food or water. Hepatitis B, C and D usually occur as a result of parenteral contact with infected body fluids. Common modes of transmission for these viruses include receipt of contaminated blood or blood products, invasive medical procedures using contaminated equipment and for hepatitis B transmission from mother to baby at birth, from family member to child, and also by sexual contact.
Acute infection may occur with limited or no symptoms, or may include symptoms such as jaundice (yellowing of the skin and eyes), dark urine, extreme fatigue, nausea, vomiting and abdominal pain.
36th World Cancer Conferences October 11-13, 2018 Zurich, Switzerland; 13th World Biomarkers Congress November 29-30, 2018 Dublin, Ireland; 4th International Congress on Epigenetics & Chromatin September 03-05, 2018 London, UK; 28th Euro Congress on Cancer Science & Therapy March 07-08, 2019 Barcelona, Spain; Vaccines Conferences Australia 2019; Global Conference on Cancer Research & Therapy (GCCRT- 2018) September 06-07, 2018 Venice, Italy; 11th Australasian Viral Hepatitis Conferences August 13-15 2018, Adelaide, Australia; 7th International Symposium on Hepatitis Care Conferences in Substance Users September 19-21 2018, Cascais, Portugal; Hepatitis C Virus and Related Viruses 25th International Symposium 2018 October 08-11 2018, Dublin, Ireland; International Hepatitis B Cure Meeting 2018 November 07, 2018 Toronto, Canada; Vaccines Conferences Canada 2019; Australasian Tuberculosis Conferences August 30-31 2018, Wellington, New Zealand
British Society for Immunology; Microbiology Society, London; Society for Applied Microbiology; European Society of Clinical Microbiology and Infectious Diseases
Track 20: Travel Immunization
Anyone planning to travel abroad may need immunizations before departure. Although few immunizations are compulsory for international travel, some are recommended for the traveller's protection. Some vaccines must be given in 2–3 doses several weeks apart. Therefore, a doctor should be consulted at least 2–3 months before departure. Children under 1 year, and people with a compromised immune system or serious underlying disorder may not be able to have some vaccinations, such as those for yellow fever and tuberculosis (BCG). Recommended vaccines are travel vaccinations that can protect you in areas where there is an intermediate or high risk for contracting certain illnesses. They also help prevent the spread of diseases from one country to another.
10th International Conferences on Clinical and Cellular Immunology August 6-7, 2018 Madrid, Spain; 11th Annual Congress on Immunology & Immunotechnology September 13-14, 2018 Zurich, Switzerland; 10th Molecular Immunology & Immunogenetics Congress March 04-05, 2019 Barcelona, Spain; 10th European Immunology Conferences June 13-14, 2019 Berlin, Germany; 19th Annual Colorado Immunology Conferences August 29-31, 2018 Colorado, USA; Vaccines Conferences USA 2019; 5th European Congress of Immunology September 02-05, 2018 Amsterdam, The Netherlands; Frontiers of Immunology in Health & Disease September 10-14, 2018 Suzhou, China; 17th International Congress of Immunology October 18-23, 2018 Beijing, China; Tumor Immunology and Immunotherapy Conferences November 27-30, 2018 Florida, USA; Vaccines Conferences Asia 2019; Innate Immune Receptors: Roles in Immunology and Beyond March 10-14, 2019 Taipei, Taiwan
Track 21: Mucosal vaccines
Most infectious agents enter the body at mucosal surfaces and therefore mucosal immune responses function as a first line of defence. Protective mucosal immune responses are most effectively induced by mucosal immunization through oral, nasal, rectal or vaginal routes, but the vast majority of vaccines in use today are administered by injection. Immunisation involves the delivery of antigens to the mucosal immune system (dispersed or organised into units such as Peyer's patches in the intestine or the nasal-associated lymphoid tissue in the oropharangeal cavity). The antigen delivery systems may comprise a simple buffer solution with/without adjuvants or an advanced particulate formulation, such as liposomes or nanoparticles. The most commonly evaluated route for mucosal antigen delivery is oral, but other routes have also been explored.
32nd International Conferences on Vaccines and Immunization March 21-22, 2019 Rome, Italy; Vaccines ConferencesJune 03-04, 2019 London, UK; ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance September 4-7 2018, Lisbon, Portugal; 12th Vaccine Congress September 16-19, 2018 Budapest, Hungary; Vaccines Conferences Middle east 2019; International Conferences on Immunology & Vaccination September 17-19, 2018 Paris, France; 2018 International Society for Vaccines (ISV) Annual Congress October 28-30 2018 Georgia, USA; World Congress on Vaccines October 29-31, 2018, Washington DC, USA; 4thInternational Conference on Vaccines Research & Development November 13-15, 2018 in Baltimore, USA; Vaccines Conferences Australia 2019; Canadian Immunization Conferences 2018 December 04–06, 2018 Ontario, Canada; Molecular Approaches to Vaccines and Immune Monitoring February 10-14, 2019 Colorado, USA; 9th Annual Vaccines World Summit 2019 February 12-13, 2019 Hyderabad, India; 3rd Global Vaccines Research & Development ConferencesMarch 25-26, 2019 Milan, Italy; World Vaccine Congress Washington 2019 April 14-17, 2019 Washington DC, USA
Swiss Society for Microbiology; Federation of European Microbiological Societies; International Society of Vaccines; Royal Society of London; Epidemiological Society of London; Edward Jenner Society; International Union of Immunological Society
Track 22: HPV Vaccines
Human Papillomavirus (HPV) vaccine is an inactivated (not live) vaccine which protects against four major types of HPV.
These include two types that cause about 70% of cervical cancer and two types that cause about 90% of genital warts. HPV vaccine can prevent most genital warts and most cases of cervical cancer. Protection from HPV vaccine is expected to be long-lasting. But vaccinated women still need cervical cancer screening because the vaccine does not protect against all HPV types that cause cervical cancer.
Routine HPV Vaccination
HPV vaccine is routinely recommended for girls 11 and 12 years of age
The HPV4 vaccine (the type recommended for prevention of genital warts in girls) may also be given in three doses to boys aged 9 to 26.
It is important for girls to get HPV vaccine before their first sexual contact -- because they have not been exposed to HPV. For these girls, the vaccine can prevent almost 100% of disease caused by the four types of HPV targeted by the vaccine. However, if a girl or woman is already infected with a type of HPV, the vaccine will not prevent disease from that type. The vaccine is also recommended for girls and women 13 through 26 years of age who did not receive it when they were younger.
32nd International Conferences on Vaccines and Immunization March 21-22, 2019 Rome, Italy; Vaccines ConferencesJune 03-04, 2019 London, UK; ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance September 4-7 2018, Lisbon, Portugal; 12th Vaccine Congress September 16-19, 2018 Budapest, Hungary; International Conferences on Immunology & Vaccination September 17-19, 2018 Paris, France; 2018 International Society for Vaccines (ISV) Annual Congress October 28-30 2018 Georgia, USA; Vaccines Conferences Canada 2019; 6th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs August 27-28, 2018 Hilton Zurich Airport, Zurich, Switzerland; Vaccines Conferences USA 2019; 9th International Workshop on HIV & Aging 2018 September 13-14, 2018, New York, USA; Australasian HIV & AIDS Conferences 2018 September 24-26, 2018 Sydney, Australia; British HIV Association Autumn Conference 2018 October 04-05, 2018, London, UK; HIV Research Conferences (HIVR4P 2018) October 21-25, 2018 Madrid, Spain; HIV Drug Therapy Glasgow 2018 October 28- 31, 2018 Glasgow, UK; HIV Vaccines Conferences March 24 - 28, 2019 | British Columbia, Canada
Slovenian Association for Allergology & Clinical Immunology; Spanish Society of Allergology and Clinical Immunology; European Federation for Immunogenetics; European Macrophage and Dendritic Cell Society
American Association of Immunologists; American Association of Pharmaceutical Scientists; American Association of Veterinary Immunologists; American Society for Histocompatibility and Immunogenetics
Israel Association of Allergy and Clinical Immunology; Jordanian Society for Allergy and Clinical Immunology; Kuwait Society of Allergy & Clinical Immunology; Japanese Society for Immunology, Japan; Singaporean Society For Immunology, Singapore; Australasian Society of Clinical Immunology and Allergy, Australia
Latest Scope, Research and Innovation in Vaccines
Vaccines Companies
Vaccines Companies in Europe: Hookipa Biotech | s-TARget Therapeutics | Valneva | GlaxoSmithKline | AXON Neuroscience | Bavarian Nordic | Onxeo | Vibalogics | BioNTech | Immatics Biotechnologies | MSD (Merck) | Okairos | Bilthoven Biologicals | ISA Pharmaceuticals | Ferrer | 2A Pharma | Anergis | Amal Therapeutics | AFFiRiS | Themis Bioscience | DanDrit Biotechnology | Abivax | InnaVirVax | APCure | Imaxio | Vaxon Biotech | VitamFero | Theravectys | Bial | Aelix Therapeutics | Mymetics | Treos Bio | Prokarium | Glide Technologies | Midatech | PsiOxus Therapeutics | ImmunoBiology (ImmBio) | Seqirus (CSL) | Scancell | Allergy Therapeutics | Oryx Translational Medicine | Provecs Medical | Vicinivax | DCPrime | ImmuneTune | Immunovo | Absynth Biologics | Oxford Vacmedix | Vaccitech
Vaccines Companies in USA: IGNITE Immunotherapy | Dynavax Technologies | Novartis Diagnostics | Entest Biomedical | ImmunoScience | Inovio Pharmaceuticals | MediGene | Novartis | Pfene | Vical | Pfizer | Celldex Therapeutics | Protein Sciences | Opko Health | GeneCure Biotechnologies | CSL Behring | Akorn | Antera Therapeutics | Matrivax Research & Development | Merck | Affinivax | Genocea Bioscience | Sanofi Pasteur | VBI Vaccines | Berg | Agenus | Xenetic Biosciences | Selecta Biosciences | PharmAthene | Medigen | MedImmune (AstraZeneca) | Altimmune | Emergent Biosolutions | Biologics Resources | Integrated BioTherapeutics | Sanaria | Wellstat Group | NanoBio | Takeda Vaccines | Liquidia Technologies | NovaDigm Therapeutics | Immunotope | Immunovaccine | Bellicum Pharmaceuticals | Cascadian Therapeutics | EpiThany | Etubics | Immune Design | Akshaya BIO | InterveXion Therapeutics | Cascadian Therapeutics | Gritstone Oncology | SutroVax | CardioVax | Tolerion | PaxVax | Adamis Pharmaceuticals | BioMedicure | MabVax Therapeutics | Polynoma | Galena Biopharma | Meissa Vaccines | Vaxart | Altravax | ImmunoCellular Therapeutics | Sinovac Biotech | Vivaldi Biosciences | EpitoGenesis | Nanotherapeutics | TapImmune | Aurora Biopharma | GeoVax | Inhibikase Therapeutics | TremRx | Immudicon | ImmusanT | Neon Therapeutics | Alopexx Vaccine (Alopexx) | OncoPep | Antigen Express (Generex Biotechnology) | PathoVax | Biofactura | Biological Mimetics | Neuralstem | Immunomic Therapeutics | SynAm Vaccine | Immunophotonics | Sequoia Sciences | Heat Biologics | Annias Immunotherapeutics | Advaxis | Agilvax | Codagenix | United Biomedical | Intellect Neurosciences | Alpha-1 Biologics | TechnoVax | PnuVax | IgY Immune Technologies & Life Sciences | Najit Technologies | UbiVac | Avax Technologies | Molecular Targeting Technologies (MTTI) | Vitruvian Biomedical | TRIA Biosciences | FluGen | Madison Vaccines
Vaccines Companies in Asia & Middle-East: Bharat Biotech | Indian Immunologicals | Shantha (Sanofi) | Panacea Biotec | Adimmune (Taichung) | Medigen Vaccine Biologics | Lipotek | Admedus | Gamma Vaccines | Sementis | BioDiem | Vaxxas Nanopatch | Sinovac Biotech | Haffkine Biopharmaceuticals | Sentinext Therapeutics | Rhapsody Biologics
List of Vaccines
Adenovirus vaccines | Alzheimer's disease amyloid protein vaccines | Bacterial diseases Vaccines | BCG vaccine | Breast cancer vaccine | Cancer Vaccine | Caries vaccine | Chagas disease vaccine | Cholera vaccine | Coxsackie B virus vaccine | Cytomegalovirus vaccine | Dengue vaccine | Diphtheria-Tetanus toxoids (DT-dT) | Diphtheria-Tetanus-wPertussis vaccine (DTwP) | DPT vaccine | DTaP vaccine | DTwP-Hep B vaccine | DTwP-HepB-Hib vaccine | DTwP-Hib vaccine | DTwP-IPV | DTwP-IPV-Hep B vaccine | DTwP-IPV-Hep B-Hib vaccine | Eastern Equine encephalitis virus vaccine | Ebola vaccine | Ehrlichiosis vaccine | Enterovirus 71 vaccine | Epstein–Barr vaccine | Haemophilus influenzae type b vaccine | Hepatitis A vaccine | Hepatitis B vaccine | Hepatitis C vaccine | Hepatitis E vaccine | Hib vaccine | HIV vaccine | Hookworm vaccine | HPV vaccine | HTLV-1 T-lymphotropic leukemia vaccine | Influenza vaccine | IPV | Japanese encephalitis vaccine | Leprosy vaccine | Lyme disease vaccine | Malaria vaccine | Marburg virus disease vaccine | Measles vaccine | Measles-Mumps-Rubella vaccine (MMR) | Measles-Rubella vaccine (MR) | Meningococcal A+C +W polysaccharide vaccine | Meningococcal A+C polysaccharide vaccine | Meningococcal conjugate vaccine | Meningococcal vaccine | MMR vaccine | MMRV vaccine | Mumps vaccine | Norovirus vaccine | Onchocerciasis river blindness vaccine | OPV | Oral Cholera vaccine | Ovarian cancer vaccine | Pertussis vaccine | Pneumococcal conjugate vaccine | Pneumococcal polysaccharide vaccine | Polio vaccine | Prostate cancer vaccine | Q fever vaccine | Rabies vaccine | Respiratory syncytial virus vaccine | Rotavirus vaccine | Rubella vaccine | Schistosomiasis vaccine | Severe acute respiratory syndrome Vaccine (SARS) | Shingles Vaccine | Smallpox vaccine | Staphylococcus aureus vaccine | Streptococcus pyogenes vaccine | Syphilis vaccine | Tetanus Toxoid vaccine (TT) | Trypanosomiasis vaccine | Tuberculosis Vaccine (BCG) | Tularemia vaccine | Typhoid vaccine | Varicella vaccine | Shingles vaccine | MMRV vaccine | Visceral leishmaniasis vaccine | West Nile virus vaccine for humans | Yellow fever vaccine | Yersinia pestis vaccine | Zika fever Vaccine
Vaccines Journals
Asian Journal of Infectious Diseases | Biotechnology Advances | Cellular Immunology | Clinical and Experimental Vaccine Research | Clinical and Vaccine Immunology | Clinical Infectious Diseases | Expert Review of Vaccines | Human Vaccines and Immunotherapeutics | Immunology Letters | International Journal of Collaborative Research on Internal Medicine & Public Health | International Journal of Vaccines and Immunization | International Journal of Vaccines and Research | Journal of Allergy and Clinical Immunology | Journal of Immunological Techniques in Infectious Diseases | Journal of Vaccines & Clinical Trials | Journal of Vaccines & Vaccination | Journal of Veterinary Medical Education | Journal of Veterinary Medical Science | Journal of Veterinary Pharmacology and Therapeutics | Journal of Virological Methods | Molecular Immunology | npj Vaccines | Open Vaccine Journal | Pediatric Infection and Vaccine | Public Health | The Journal of Pediatrics | The Journal of Pediatrics | The Lancet | The Pediatric Infectious Diseases | Therapeutic Advances in Vaccines | Trials in Vaccinology | Vaccimonitor | Vaccines | Veterinary Clinical Pathology | Veterinary Immunology and Immunopathology | Veterinary Microbiology | Virology | World Journal of Vaccines | African Journal of AIDS Research | Annual Review of Immunology | Archives of Pediatric Infectious Diseases | Cancer Immunology, Immunotherapy | Current HIV Research | European Journal of Immunology | Immunological Reviews | International Immunology | Iranian Journal of Immunology | Journal of AIDS and Clinical Research | Journal of Clinical Immunology | Journal of Immunology | Journal of Infectious Diseases | Journal of Travel Medicine | Journal of Virology | Microbiology and Immunology | OncoImmunology | Open Immunology Journal | Open Infectious Diseases Journal | The Lancet Infectious Diseases | The Lancet HIV | Therapeutic Advances in Infectious Disease | Ticks and Tick-borne Diseases | Tropical Medicine and Health | Viral Immunology
Vaccines Conferences advisory board invites all the participants across the world to attend "36th Euro Global Summit and Expo on Vaccines & Vaccination" going to be held during June 03-04, 2019 in London, UK. The Theme of the conference is "Focusing on novel strategies in Vaccines research and Development" will explore the advances in Vaccines and vaccination.
Importance & Scope:
This conference could be an exceptional event that brings along a novel and International mixture of huge and medium cognizance on vaccines and vaccination, leading universities engendering the conference an ideal platform to apportion expertise, foster collaborations across trade and world, and assess elevating technologies across the world.
Vaccination is a key to eradicate the diseases. It is a subject for the professionals who looks beyond the clinical prospects. Traditional approaches to vaccine design were to emasculate or inactivate the human pathogen or a cognate animal homologue, Vaccinology is the science of vaccine development and how the immune system responds to vaccines, but additionally includes perpetual evaluation of immunization programs and vaccine safety and efficacy, as well as surveillance of the epidemiology of vaccine-preventable diseases. This chapter provides a brief overview of some of the main concepts of immunology and Vaccinology as they relate to immunization. Euro Vaccines 2019 amasses all the extroverts under one roof of current advances.
Market Growth of Vaccine Research in the last and upcoming ten years
The global vaccines market is one of the fastest growing segments and new predictions estimate the value of the market to reach between $48 billion and more than $70 billion over the next five to eight years.
According to a new report released by Transparency Market Research, the value of the global human vaccines market is expected to grow from a $28.3 billion in 2015 to $72.5 billion in 2024. The projection would represent a compound annual growth rate (CAGR) of 11.2% from 2016 to 2024. Even though the dollar figure is large and growing, vaccines still only account 3% of the market share within the global pharmaceutical industry. The report broke down expectations by segments. By age group, paediatric vaccines accounted for 57.5% of the share in 2015, but adult vaccines are expected to grow at a 13.2% CAGR during the forecast period. When the research group analysed the market by product, they found the pneumococcal segment to have the majority share in 2015, but expect hepatitis products to demonstrate strong growth through 2024. By vaccine type, the conjugate vaccines held the majority share in 2015, but the combination vaccines were expected to have the largest CAGR.
Human Vaccines - Infectious & Non Infectious Diseases
Vaccine Research & Development
HIV/AIDS Vaccines
Vaccine Safety & Efficacy
Vaccines Business Development
Cancer Vaccines and Immunotherapy
Childhood and Maternal Vaccines
Veterinary Vaccines
Vaccines for Older Adults
Human Preventive & Therapeutic Vaccines
Vaccines for Respiratory Diseases
DNA Vaccines
Hepatitis Vaccines
Vaccines against Vector-borne Diseases
Plant-based Vaccines
Travel Immunization
Vaccines against Viral & Bacterial Diseases
Next-Generation Vaccines Delivery Technologies
Immunology/Animal Models
Mucosal Vaccines
HPV Vaccines
To share your views and research, please click here to register for the Conference.
To Collaborate Scientific Professionals around the World
Conference Date June 03-04, 2019
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2
Poster Opportunity Closed Click Here to View
All accepted abstracts will be published in respective Our International Journals.
Journal of Vaccines & Vaccination
Journal of Clinical & Cellular Immunology
Journal of Immunome Research
Abstracts will be provided with Digital Object Identifier by
eurovaccines@europeannualconferences.info


text:
Observation of X-ray transient XTE J1748-288 by the Indian X-ray astronomy experiment
S. Naik 1, P.C. Agrawal 1, B. Paul 1,2, A.R. Rao 1, S. Seetha 3 and K. Kasturirangan 3
1 Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai - 400 005, India
2 Institute of Space and Astronautical Science, 3-1-1 Yoshinodai, Sagamihara, Kanagawa 229-8510, Japan
3 ISRO Satellite Center, Airport Road, Vimanapura P.O., Bangalore - 560017, India
Received 15 March 1999 / Accepted 7 January 2000
The observations of a newly discovered X-ray transient source XTE J1748-288 were made in the energy band 2 - 18 keV with the Indian X-ray Astronomy Experiment(IXAE) on the IRS-P3 satellite during 1998, June 14-25. The source count rate declined gradually with an exponential decay time of 19 1.6 days. The X-ray light curves showed no significant intensity variations on short time scales ( 10s). The power density spectrum obtained from timing analysis of the data shows no quasi-periodic oscillations in the frequency range of 0.002 Hz to 5 Hz. From the observed X-ray and radio characteristics, it is suggested that the X-ray source in XTE J1748-288 is more likely to be a black hole rather than a neutron star.
Key words: accretion, accretion disks black hole physics stars: individual: XTE J1748-288 X-rays: stars
Send offprint requests to: S. Naik (sachi@tifr.res.in)
2. Instrument and observations
3. Analysis and results
3.1. Long-term X-ray light curve
3.2. Light curves of individual observations
3.3. The power density spectrum
Online publication: February 25, 2000

redpajama_set_name: RedPajamaCommonCrawl


text:
Reiman School of Finance offers out-of-office development
The Reiman School of Finance at the University of Denver's Daniels College of Business is helping finance professionals keep their finger on the pulse.
Throughout the year, the School offers forums and workshops on new business models and trends and professional development for finance and strategy managers.
On May 3, the Spring Finance Forum Breakfast will discuss FinTech, a new financial industry that applies technology to improve financial activities. FinTech firm representatives will share their insights on how FinTech will potentially change current and future business models. Learn more about the forum here.
On May 8-10, Executive Education at the Daniels College of Business is hosting a Strategic Finance workshop on integrating financial analysis with the strategy and management of organizations. Reiman School of Finance Professors Ron Rizzuto and Randy Lewis, along with Executive Education, developed the curriculum. Find out more about Executive Education and how it is empowering leaders in business.
Scott Reiman is an alumnus and longtime member of the University of Denver community and the namesake of the Reiman School of Finance.
As CEO and founder of Hexagon, a Denver-based private investment company, he has a long and established history of business leadership in Colorado and fosters developing current and future business leaders.
Scott Reiman Supports Organizations Making an Impact
Scott Reiman and his firm Hexagon supports organizations that foster local business and emerging business leaders throughout Colorado. The Colorado Impact Fund (CIF) does just that, and more.
The CIF is a Denver-based equity fund that supports Colorado companies that generate a positive impact – both on their communities and in consistent investment returns.
The Fund invests in areas of community health, education and workforce development, natural resource conservation and economic development. It supports female and minority entrepreneurs and core industries in Colorado that hold exemplary best practices.
Funded by Colorado investors, exclusively for Colorado companies, this private equity fund provides entrepreneurs with cost-efficient capital and a network of strategic business advisors.
Since its inception in 2014, the fund has invested in 10 companies to develop and expand throughout Colorado. Together, these companies employ 648 individuals and have created 161 new jobs. Their business leadership is diverse with 50% having female founders and 20% having minority founders. These companies are also located in emerging communities where 70% are headquartered in low to middle income areas.
From empowering teachers, administrators and school-community stakeholders to boost educational outcomes with Schoolrunner, to improving cost efficiency and patient satisfaction with the healthcare system through Cirrus MD, every organization in the CIF portfolio is able to leverage the capital provided by the Fund to ultimately give back and make an impact on their community and beyond.
The other companies invested by CIF:
Kapteyn-Murnane (KM) Labs
Keystone Tower Systems
Maria Empanada
SecureSet Academy
Ashley Buderus named CEO of Quarterly Forum
Ashley Buderus named CEO of Quarterly Forum. Image courtesy of the Denver Business Journal.
Ashley Buderus, a former director with the Children's Hospital Colorado Foundation, has been appointed CEO of Quarterly Forum.
Buderus has an extensive background in non-profit organizations in Colorado in addition to the Children's Hospital Foundation, including the El Pomar Foundation and the University of Denver.
The Quarterly Forum is a nonprofit organization that strives to connect, educate and inspire Colorado's emerging business leaders.
The Forum also supports the state's future through scholarship programs, including the Scott Reiman Emerging Leader Scholarship, funded by Scott Reiman, a forum member, to provide scholarship funds to an outstanding University of Denver student.
Read more about the Forum and Buderus in her new role as CEO in the Denver Business Journal.
DU students develop ride-sharing app Wanderlift
DU students create ride-sharing app, Wanderlift.
When DU students Meredith Gee and Sam Schooler needed a ride to the mountains but didn't have one, they had an idea to create a mobile app that would get them there – Wanderlift.
For the last nine months, the two sophomores developed their idea and expanded their team.
Juniors Daniel Farrell and Lucio Franco joined the team last fall and helped launch the app and expand the group's efforts to the University of Colorado in Boulder.
Whether it's a hike at Red Rocks, a ski trip to Vail or a ride out with friends, people who need a ride to their next adventure can now use Wanderlift to get there. They can also sign up to drive, post their own trips or search for someone looking to catch a ride.
Many students say it's more affordable than other ride-sharing apps such as Lyft and Uber.
In the future, the students told 7News they hope Wanderlift helps with traffic in lessening the hourslong commute typical with heading to the hills.
The Wanderlift is available in downtown Denver, University of Denver and the University of Colorado. Find the app on the Wanderlift website and the Apple store. Soon, it will be available for Android phones.
The students credit the University for bringing them together. They all met through the schools' living and learning communities and are involved in the Center for Sustainability and entrepreneurship club through the Daniels College of Business.
As the namesake of the Reiman School of Finance in the Daniels College of Business, Scott Reiman is a longtime member of the University community and dedicated to advancing the academic and leadership success of its students. He makes contributions to the schools' growth and prosperity where students like Gee, Schooler, Farrell and Franco come up with their great ideas.


Southern Steel manufactures and supplies fabricated steel products specifically designed to European and American construction norms as well as international seismic standards for major construction projects and international companies operating in Haiti and in the region. In addition, we are proud to be certified by the American Welding Society (ASW).
Southern Steel is equipped and capable of meeting all metallic structure construction needs and also able to manufacture elements of standard or custom metal forms.
Our services, structure and expertise enable us to answer any and all specific requests related to the industry.
The construction sector is the second most important job provider in the country in which the GB Group has been continuously investing since 1972.
Dynamic and proactive, GB Group companies are strategically positioned as some of the most reliable key products manufacturers & suppliers.
With many opportunities to improve Haitian construction standards, we are investing heavily in our people and existing production facilities to maintain our position as market leader as well as engaging in new aggressive endeavors such as Southern Steel.


text:
Zeus Capital leads £13.7m Sumo Group (SUMO.L) fundraise
Sumo Group, the award winning creative and development service provider to the video games and entertainment industries, has announced a successful placing of £13.7m, in a deal led by investment banking boutique Zeus Capital.
Listing on London's Alternative Investment Market (AIM) in December 2017, on which Zeus Capital acted as nominated adviser and sole broker, Sumo Group's operating businesses include Sumo Digital and Atomhawk. Sumo Digital, the primary business, is one of the UK's largest independent developers of AAA-rated video games, whilst Atomhawk is a multi-award winning visual design company servicing the games, film and visual effects industries, acquired in June 2017.
Since completing the IPO in 2017, where Sumo Group had a market capitalisation of £145m, the company has continued to grow, both organically and through acquisition, with studios now across the UK, India and Canada. As a result, Sumo Group's market capitalisation has grown to be currently in excess of £275m.
The Group intends to use the net proceeds of the placing to take advantage of potential M&A opportunities that may arise. Given the fragmented nature of the market and opportunities arising from the Covid-19 situation, Sumo Group continues to be focused on accelerating expansion through specifically targeted acquisitions.
A team at Zeus Capital, comprising of directors of corporate finance Andrew Jones and Richard Darlington, corporate finance associate Ed Stevenson, corporate finance analyst Matt Hogg and director of equity capital markets Benjamin Robertson, acted as joint bookrunner, joint broker and nomad on the transaction.
The new shares have been admitted to trading on the London Stock Exchange's AIM market on 21st July, with the placing representing five per cent of the enlarged share capital.
This web page constitutes a financial promotion for the purposes of section 21 of the Financial Services and Markets Act 2000 and has been approved by Zeus Capital Limited, which is authorised and regulated by the Financial Conduct Authority
Insig AI
Sector: Technology
Type: Fundraise
Surface Transforms
Sector: Automobiles & Parts
boohoo Group plc
Sector: General Retailers
Xafinity plc
Benjamin Robertson
Director, Equity Capital Markets
Richard Darlington
Director, Corporate Finance
Andrew Jones


Bay City Cooperative Market is now a member of the Cooperative Grocer Network!
The Cooperative Grocer Network (CGN) is a nonprofit, 501(c)6 trade association intent on strengthening all retail food co-ops by a creating a community of cooperators who can develop and share their best resources and practices. CGN provides extensive online resources for peer support. As new co-ops get up and running, the network offers a place for them to gain insights every day, based on the experience of established stores. It follows number 6 of the 7 Principle of Cooperation — co-ops help each other!
The BCCM board also has some exciting news that we'll be sharing details on in the coming months: We've received the largest grant of our efforts to date! The grant is a Rural Seed Grant that comes from Food Cooperative Initiative and is to be used for outreach to our community. We shared the announcement of this grant on Facebook and Instagram, but we can't wait to talk about this opportunity in greater depth once all of the details are worked out. Watch for more information soon!


Citizens can be literally expelled from the political community by the President, through his decision to block them, which is the subject of a lawsuit.
I've written previously about the function, power, and legal significance of presidential rhetoric (including touching on the topic in previous Take Care pieces, here and here). But this book left me thinking about a distinct aspect of presidential speech: its power to create and define the political community.
Modern American presidents have mostly been expansive in their efforts to do that: they have largely attempted, even if imperfectly, to draw relatively broad boundaries around the members of the polity. That's not true about the charismatic populists who play leading roles in the stories of democratic decline the book tells. Drawing on the work of political theorist Jan-Werner Müller, Ginsburg and Huq identify as a key feature of populist leaders their tendency to assert a "'moralized antipluralism,' based on a belief that 'they, and they alone, represent the people.'" This often entails defining "the people" in contrast to other groups—political and cultural elites; immigrants; political opponents; members of religious or racial minorities. In this light, a 2016 campaign statement by Donald Trump that "the only important thing is the unification of the people—because the other people don't mean anything," takes on a decidedly ominous cast. And of course, there have been countless similar statements since.
It's impossible to reflect on President Trump's rhetoric without also considering his preferred medium of communication—twitter. And the book's discussion of populist rhetoric made me wonder whether there's something meaningful about the selection of twitter that I hadn't spent much time reflecting on: that it is a medium that allows the speaker to address an identified group of "followers," who self-select into the political community and then become stand-ins for the entirety of it.
More than just self-selecting in, they can be literally expelled from the community by the President, through his decision to block them, which is the subject of a lawsuit currently pending before the Second Circuit. The blocked plaintiffs prevailed in the district court, which found that when the President blocks users in response to their criticisms of him or his policies (the Administration has conceded that this is the reason for the blocking), he violates the First Amendment by engaging in impermissible viewpoint discrimination.
After the Administration's loss in the district court, it seemed to me all but certain that the Administration would capitulate—that attorneys in the Department of Justice or the White House Counsel's Office would persuade the President that continuing to fight this suit was a poor use of DOJ resources, and in addition risked establishing precedent that would be adverse to the institutional interests of the presidency. So I was confident that rather than continuing to fight this case, the President would eventually agree to stop blocking critics.
When DOJ announced that it would be appealing this case to the Second Circuit, I assumed that no one had been able to focus the President's attention on the issue long enough to make the case that the appeal should be abandoned—not that it reflected the considered choice of the President and his advisors.
But this book has made me wonder whether at issue in the case is a principle the President very much deems worth fighting for—the right to render literal what scholars like Huq and Ginsburg have described in more conceptual terms—the power to identify, demarcate, and constrict the boundaries of the political community. In that regard, what the courts do with this case may have implications well beyond First Amendment doctrine.
Originally published by Take Care under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license.


text:
Q: ProGuard causing Jackson error, "Conflicting property name definitions" I am using the Nest Android SDK and am getting close to releasing my application. I have found that it is not possible to use Proguard with the Nest SDK as it stands today. Once a user is authenticated, the data that comes back causes the crash below.
How can I get passed this, and still keep ProGuard enabled? I created an issue on the github page but I assume it will not be a high priority by Nest.
09-06 23:49:32.807 15229-15229/? E/AndroidRuntime: FATAL EXCEPTION: main
Process: <my_package>, PID: 15229
java.lang.IllegalStateException: Conflicting property name definitions: 'locale' (for [field com.nestlabs.sdk.Device#b]) vs 'name' (for [method com.nestlabs.sdk.Device#b(0 params)])
at com.fasterxml.jackson.databind.introspect.POJOPropertyBuilder.findRenamed(Unknown Source)
at com.fasterxml.jackson.databind.introspect.POJOPropertyBuilder.findNewName(Unknown Source)
at com.fasterxml.jackson.databind.introspect.POJOPropertiesCollector._renameProperties(Unknown Source)
at com.fasterxml.jackson.databind.introspect.POJOPropertiesCollector.collect(Unknown Source)
at com.fasterxml.jackson.databind.introspect.BasicClassIntrospector.collectProperties(Unknown Source)
at com.fasterxml.jackson.databind.introspect.BasicClassIntrospector.forDeserialization(Unknown Source)
at com.fasterxml.jackson.databind.introspect.BasicClassIntrospector.forDeserialization(Unknown Source)
at com.fasterxml.jackson.databind.DeserializationConfig.introspect(Unknown Source)
at com.fasterxml.jackson.databind.deser.DeserializerCache._createDeserializer(Unknown Source)
at com.fasterxml.jackson.databind.deser.DeserializerCache._createAndCache2(Unknown Source)
at com.fasterxml.jackson.databind.deser.DeserializerCache._createAndCacheValueDeserializer(Unknown Source)
at com.fasterxml.jackson.databind.deser.DeserializerCache.findValueDeserializer(Unknown Source)
at com.fasterxml.jackson.databind.DeserializationContext.findRootValueDeserializer(Unknown Source)
at com.fasterxml.jackson.databind.ObjectMapper._findRootDeserializer(Unknown Source)
at com.fasterxml.jackson.databind.ObjectMapper._readMapAndClose(Unknown Source)
at com.fasterxml.jackson.databind.ObjectMapper.readValue(Unknown Source)
at com.firebase.client.d.a(Unknown Source)
at com.nestlabs.sdk.aa.a(Unknown Source)
at com.firebase.client.c.ba.run(Unknown Source)
at android.os.Handler.handleCallback(Handler.java:739)
at android.os.Handler.dispatchMessage(Handler.java:95)
at android.os.Looper.loop(Looper.java:148)
at android.app.ActivityThread.main(ActivityThread.java:5417)
at java.lang.reflect.Method.invoke(Native Method)
at com.android.internal.os.ZygoteInit$MethodAndArgsCaller.run(ZygoteInit.java:726)
at com.android.internal.os.ZygoteInit.main(ZygoteInit.java:616)

redpajama_set_name: RedPajamaStackExchange


Arrow Films are pleased to announce the DVD Box Set release of Jean Reno's hit Parisian Cop drama Jo on 5th August 2013.
In his first TV series role since the 1980s, Reno plays Jo St-Clair, a veteran detective in Paris's elite Criminal Brigade, tackling the city's most challenging murder cases.
From René Balcer, the Emmy® winning producer of Law & Order and an all-star line-up of directors, including Charlotte Sieling (The Killing, The Bridge), Jo's unique storylines take its audience behind-the-scenes at some of Paris' most iconic locations. Heinous crimes are committed in the picturesque settings of the Eiffel Tower, Notre Dame, the Catacombs and Place Vendome.
As we follow St-Clair on his pursuit of justice, the extent of the turmoil in his personal life becomes apparent - a recently deceased wife and long estrangement from his damaged daughter combine with a fight against drink and drug addiction, creating the perfect storm of loneliness.
Finding solace in his brilliant but brutal police work, St-Clair locks horns with pathological killers to solve a series of shocking murders.
Alongside Jean Reno are Tom Austen (The Borgias), who plays Boyard, Jo's college-educated rookie partner and Jill Hennessy (Crossing Jordan) as Karyn, Jo's adviser and friend. Boyard's by-the-book approach is an entertaining contrast to Jo's no holds barred methods.
Supervising the Criminal Brigade is tough-minded police chief Commisaire Dormont, wonderfully portrayed by Irish-born actress Orla Brady, who has suffered a long and turbulent history with Saint-Clair.
Following the success of their French cop-thriller Braquo and the sultry and sensual Maison Close, Arrow Films are proud to be bringing yet another top-quality Gallic drama to the UK.
Episode 4 - "The Invalides" 35-year-old Mirage fighter pilot Charlotte Dumas is found dead inside Les Invalides wearing a ring stolen in a notorious unsolved murder. The main suspect is a mechanic in Charlotte's crew who had a controversial relationship.
Episode 5 - "Place Vendome" In a garage under Place Vendome, firemen find a burnt corpse behind the wheel of a car. The cops identify Philip Roquin, an accountant at a jewellery store. His family and employer's testimonies differ but who is lying?
Episode 6 - "Le Marais" Place Des Vosges, a stone's throw from Victor Hugo's apartment. A young woman is found dead from a blunt-force head wound. Jo deducts the murder was not premeditated but more likely a crime of passion.
Episode 7 - "Opera" On a sunny afternoon after taking his daughter to her ballet lesson, a middle-aged man gets stabbed on the steps of the Palais Garnier. The victim being an economist and a family man, everything suggests the murder was random.
Episode 8 - "The Catacombs" A young woman is found stabbed to death in the Catacombs, an area known popular with Goth teenagers and would-be Satanists. Suspicion at first falls on those two groups but the style of the killing suggests a sexual motive.


I've been thinking about the intangible connection you have to someone you have a special bond with. My father passed away a few days ago and the 12 hours beforehand were a nightmare for me. I was completely distraught about everything in my life. I couldn't stop thinking of all the things that were wrong both real and imagined in nearly every aspect of my life.
I kept thinking a lot about my Dad during that time. Things I hadn't thought about in years. Like the time he built us a tree house or stayed up all night assembling bikes so they were under the tree when we woke up Christmas morning. I wondered if the reason I was thinking so much about him was because I knew he was dying. I later realized that I looked at the clock and thought about him at the exact time that he passed away.
He was a very kind and intelligent man who earned his degree in Engineering from Lehigh University. He and my mother were married for 34 years until her death in 2000. They were always very respectful of each other and that is something very important to me to model in my own life. I don't always succeed but it will always be a life time goal for me.
While he was a great man he wasn't perfect. He was very quiet and hard to get to know. He was always there physically but at time it was hard to connect on a deep emotional level. I never thought about it when I was younger. It was just the way he was. I know now this has made deep intimacy somewhat uncomfortable for me but if that was the worse thing that he did, I consider myself pretty lucky. Now that I am aware of why it makes me uncomfortable it helps when I struggle. Being conscious of it has also pushed me to look for ways to be more open and vulnerable. Submission is the main place where I have done this. While it is terrifying to be vulnerable sometimes, the openness and release I have found by letting go of my walls has been life changing.
Despite the upheaval of the week, it has been very important to me to keep my obligations to Sir. I went to one yoga class last night and got up and went again at 6am since I know I will be out of town until Sunday. I am also writing my required blog post. This consistency and routine gives me a sense of stability that a lack anywhere else in my life.


Time to move these along to a deserving home, the perfect Xmas gift for the discerning EC lover in your life (maybe its you!). these are mostly higher grade with at least one GFC and one Pedigree in the batch. Shipping is a flat rate $13 for any size order via USPS Priority mail, I will accept Paypal, for other forms of payment please check with me first. I am open to trades for Fox or Ace books that I need. No probates or HOSer's please!
Now I can afford to buy more books from you Rick! Thanks!!!
That's it for now, I may come back later with some raw mid grade Sci Fi additions, thanks for looking!
One of my absolute favorite Wood covers...so awesome! Good luck with the sale!
Weird Science #5, #10, and #11.
Can you post the label please?
Here you go, back cover as well.


text:
La Haus am Horn è un prototipo di abitazione costruito per la mostra del Bauhaus a Weimar nel 1923.

È stata progettata da Georg Muche, pittore e insegnante al Bauhaus. Altri insegnanti, come Adolf Meyer e Walter Gropius, hanno fornito assistenza per gli aspetti tecnici della progettazione della casa.

Gropius affermava che l'obiettivo della costruzione della casa era il massimo comfort con la massima economia grazie all'applicazione della migliore artigianalità e la migliore distribuzione degli spazi come forma, dimensione e articolazione. La costruzione della casa è stata finanziata da Sommerfeld, un commerciante di legname di Berlino, che era stato un cliente di Gropius anni prima.
La casa è stata costruita lontano dalla sezione principale del Bauhaus, su un terreno che veniva usato come un orto per la scuola. Il sito è vicino al Parco an der Ilm a Weimar, in una strada residenziale.

Altri progetti

Collegamenti esterni

Bauhaus
Patrimoni dell'umanità della Germania

redpajama_set_name: RedPajamaWikipedia